Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, Bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis,...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, Bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
